Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study

被引：21

作者：

Modi, S.

Tsurutani, J.

Tamura, K.

Park, H.

Sagara, Y.

Murthy, R.

Iwata, H.

Krop, I. E.

Doi, T.

Redfern, C.

Moreno-Aspitia, A.

Redman, R.

Lee, C.

Sugihara, M.

Fujisaki, Y.

Takahashi, S.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Kindai Univ, Fac Med, Osaka, Japan

[3] Natl Canc Ctr, Tokyo, Japan

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Hakuaikai Sagara Hosp, Social Med Corp, Kagoshima, Japan

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Natl Canc Ctr Hosp East, Chiba, Japan

[10] Sharp HealthCare, San Diego, CA USA

[11] Mayo Clin, Jacksonville, FL 32224 USA

[12] Univ Louisville, Louisville, KY 40292 USA

[13] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[14] Daiichi Sankyo Co Ltd, Tokyo, Japan

[15] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

来源：

关键词：

D O I：

10.1158/1538-7445.SABCS18-P6-17-02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P6-17-02

引用

页数：2